熱門資訊> 正文

Viridian Therapeutics推出2.5亿美元的同时债务和股权发行

2026-05-06 04:24

Viridian Therapeutics, Inc.(VRDN) 0
安進公司(AMGN) 0

Viridian Therapeutics (NASDAQ: VRDN) on Tuesday said that it has commenced concurrent public offerings of $150 million in convertible senior notes due 2032 and $100 million of common stock and convertible preferred stock.
The company said it may grant underwriters a 30-day option to purchase up to an additional 15% of securities in each offering.
Viridian plans to use the proceeds to repay outstanding debt, fund market expansion studies and research and development, and for general corporate purposes.
VRDN -5.23% after hours to $17.80.
Source: Press Release

More on Viridian Therapeutics

Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease - Slideshow
Stocks to watch on Monday after market: VRDN, BSX, MTB, AL
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。